Cyclophosphamide and bortezomib with prednisone or dexamethasone for the treatment of relapsed and refractory multiple myeloma

Clinical trials of the combination of cyclophosphamide, bortezomib and steroids in relapsed/refractory myeloma have shown promising results, but there is little information about real-world outcomes. We retrospectively reviewed the results of weekly CyBorP(D) in 96 patients treated off study. The overall response rate was 69%; median PFS was 16.2 months. Toxicity was mild with low rates of myelosuppression and neuropathy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research